BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
BioAge Labs, Inc.NASDAQ: BIOA
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI falls 72.3% from a year ago
Accumulated OCI stood at $73K at the end of Q1 FY2026, down 72.3% from a year earlier and down 73.7% from the prior quarter. Over 3 fiscal years it compounded at +18.5% a year.
Context
- Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -72.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 278K USD
- Year-over-year change
- +13.5%
- 3-year CAGR
- +18.5%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 278K | +13.5% |
| FY2024 | 2024-12-31 | 245K | +49.4% |
| FY2023 | 2023-12-31 | 164K | -1.8% |
| FY2022 | 2022-12-31 | 167K | — |
Accumulated OCI vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -72.3% is the 2nd highest of 6, against a peer median of -182.2%.
- Accumulated OCI amounts to 0.0% of total assets for BIOA, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$10.53M CAD | +1868.2% | — | 0.9% | |
BIOABioAge Labs, Inc. | Mar 2026 | $73K USD | -72.3% | +18.5% | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Dec 2025 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | -$97K USD | -182.2% | — | 0.0% | |
| Mar 2026 | -$183K USD | -525.6% | — | 0.0% | |
| Mar 2026 | -CA$214.15M CAD | -283.0% | — | 35.5% | |
| Peer median (excluding BIOA) | — | -182.2% | — | 0.0% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.